News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DARA BioSciences, Inc. to Present Results of a Clinical Study for KRN5500 at the "Annual Targeting Pain with Novel Therapeutics" Meeting Sponsored by Cambridge Healthtech Institute



2/22/2010 8:33:21 AM

RALEIGH, N.C., Feb. 22, 2010 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the results of its Phase 2 study has been identified by Cambridge Healthtech Institute ("CHI") for inclusion in its Annual "Targeting Pain with Novel Therapeutics" Conference.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES